INDV vs PGNY: fair value comparison
Indivior Pharmaceuticals, Inc. and Progyny, Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, INDV currently sits closer to the top of our discount ranking. PGNY carries the stronger quality grade.
| INDV | PGNY | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $37.37 | $31.53 |
| 12-month range | $23.46–$40.25 | $16.86–$31.53 |
| Sector rank | #29 of 113 Healthcare | #31 of 113 Healthcare |
| Quality grade | F | A |
| Leverage | Low | Low |
| Margin trend | Stable | Expanding |
| Revenue growth | Modest | Strong |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | Mixed | Uptrend |
| DCF cross-check | Overvalued | Undervalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: INDV fair value analysis · PGNY fair value analysis